Radnet Inc (RDNT)

$37.475

-0.87

(-2.26%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on Radnet Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 403.71M → 401.96M (in $), with an average decrease of 0.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -14.28M → 17.54M (in $), with an average increase of 161.5% per quarter

Performance

  • $36.48
    $38.21
    $37.48
    downward going graph

    2.66%

    Downside

    Day's Volatility :4.52%

    Upside

    1.91%

    downward going graph
  • $20.83
    $39.55
    $37.48
    downward going graph

    44.42%

    Downside

    52 Weeks Volatility :47.33%

    Upside

    5.23%

    downward going graph

Returns

PeriodRadnet IncSector (Health Care)Index (Russel 2000)
3 Months
17.36%
13.2%
0.0%
6 Months
20.76%
9.7%
0.0%
1 Year
62.56%
15.4%
-6.7%
3 Years
97.53%
30.3%
-19.6%

Highlights

Market Capitalization
2.6B
Book Value
$9.12
Earnings Per Share (EPS)
0.06
PE Ratio
645.0
PEG Ratio
2.32
Wall Street Target Price
41.0
Profit Margin
0.25%
Operating Margin TTM
7.0%
Return On Assets TTM
2.27%
Return On Equity TTM
4.67%
Revenue TTM
1.6B
Revenue Per Share TTM
25.97
Quarterly Revenue Growth YOY
14.799999999999999%
Gross Profit TTM
288.8M
EBITDA
215.8M
Diluted Eps TTM
0.06
Quarterly Earnings Growth YOY
24.0
EPS Estimate Current Year
0.46
EPS Estimate Next Year
0.58
EPS Estimate Current Quarter
0.06
EPS Estimate Next Quarter
0.15

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Radnet Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 9.41%

Current $37.48
Target $41.00

Company Financials

FY18Y/Y Change
Revenue
975.1M
↑ 5.74%
Net Income
32.2M
↑ 60735.85%
Net Profit Margin
3.31%
↑ 3.3%
FY19Y/Y Change
Revenue
1.2B
↑ 18.36%
Net Income
23.4M
↓ 27.3%
Net Profit Margin
2.03%
↓ 1.28%
FY20Y/Y Change
Revenue
1.1B
↓ 7.13%
Net Income
-1.7M
↓ 107.46%
Net Profit Margin
-0.16%
↓ 2.19%
FY21Y/Y Change
Revenue
1.3B
↑ 22.69%
Net Income
44.3M
↓ 2633.96%
Net Profit Margin
3.37%
↑ 3.53%
FY22Y/Y Change
Revenue
1.4B
↑ 8.74%
Net Income
33.6M
↓ 24.17%
Net Profit Margin
2.35%
↓ 1.02%
FY23Y/Y Change
Revenue
1.6B
↑ 10.49%
Net Income
4.0M
↓ 88.19%
Net Profit Margin
0.25%
↓ 2.1%
Q2 FY22Q/Q Change
Revenue
354.4M
↑ 3.69%
Net Income
13.8M
↑ 65.38%
Net Profit Margin
3.9%
↑ 1.45%
Q3 FY22Q/Q Change
Revenue
350.0M
↓ 1.22%
Net Income
6.4M
↓ 53.39%
Net Profit Margin
1.84%
↓ 2.06%
Q4 FY22Q/Q Change
Revenue
383.9M
↑ 9.66%
Net Income
5.0M
↓ 22.93%
Net Profit Margin
1.29%
↓ 0.55%
Q1 FY23Q/Q Change
Revenue
390.6M
↑ 1.74%
Net Income
-14.3M
↓ 387.44%
Net Profit Margin
-3.66%
↓ 4.95%
Q2 FY23Q/Q Change
Revenue
403.7M
↑ 3.37%
Net Income
8.4M
↓ 158.59%
Net Profit Margin
2.07%
↑ 5.73%
Q3 FY23Q/Q Change
Revenue
402.0M
↓ 0.43%
Net Income
17.5M
↑ 109.58%
Net Profit Margin
4.36%
↑ 2.29%
FY17Y/Y Change
Total Assets
869.0M
↑ 2.3%
Total Liabilities
799.1M
↑ 0.2%
FY18Y/Y Change
Total Assets
1.1B
↑ 27.66%
Total Liabilities
909.1M
↑ 13.77%
FY19Y/Y Change
Total Assets
1.6B
↑ 48.34%
Total Liabilities
1.4B
↑ 55.37%
FY20Y/Y Change
Total Assets
1.8B
↑ 8.57%
Total Liabilities
1.5B
↑ 8.2%
FY21Y/Y Change
Total Assets
2.1B
↑ 15.21%
Total Liabilities
1.7B
↑ 12.04%
FY22Y/Y Change
Total Assets
2.4B
↑ 18.24%
Total Liabilities
1.9B
↑ 13.44%
Q2 FY22Q/Q Change
Total Assets
2.2B
↑ 4.63%
Total Liabilities
1.8B
↑ 4.03%
Q3 FY22Q/Q Change
Total Assets
2.2B
↑ 0.29%
Total Liabilities
1.8B
↓ 0.03%
Q4 FY22Q/Q Change
Total Assets
2.4B
↑ 8.31%
Total Liabilities
1.9B
↑ 8.59%
Q1 FY23Q/Q Change
Total Assets
2.4B
↓ 0.82%
Total Liabilities
1.9B
↓ 1.11%
Q2 FY23Q/Q Change
Total Assets
2.7B
↑ 12.06%
Total Liabilities
1.9B
↑ 1.21%
Q3 FY23Q/Q Change
Total Assets
2.7B
↓ 0.64%
Total Liabilities
1.9B
↓ 2.7%
FY18Y/Y Change
Operating Cash Flow
116.8M
↓ 17.31%
Investing Cash Flow
-146.7M
↑ 85.01%
Financing Cash Flow
-10.9M
↓ 66.29%
FY19Y/Y Change
Operating Cash Flow
104.3M
↓ 10.65%
Investing Cash Flow
-99.5M
↓ 32.22%
Financing Cash Flow
25.0M
↓ 329.56%
FY20Y/Y Change
Operating Cash Flow
233.8M
↑ 124.07%
Investing Cash Flow
-126.2M
↑ 26.92%
Financing Cash Flow
-45.6M
↓ 282.6%
FY21Y/Y Change
Operating Cash Flow
149.5M
↓ 36.05%
Investing Cash Flow
-221.5M
↑ 75.46%
Financing Cash Flow
104.7M
↓ 329.74%
FY22Y/Y Change
Operating Cash Flow
146.4M
↓ 2.06%
Investing Cash Flow
-246.9M
↑ 11.48%
Financing Cash Flow
93.6M
↓ 10.53%
Q2 FY22Q/Q Change
Operating Cash Flow
64.8M
↑ 7096.78%
Investing Cash Flow
-34.4M
↓ 44.08%
Financing Cash Flow
-3.3M
↓ 0.03%
Q3 FY22Q/Q Change
Operating Cash Flow
27.0M
↓ 58.32%
Investing Cash Flow
-27.1M
↓ 21.39%
Financing Cash Flow
-3.3M
↑ 0.03%
Q4 FY22Q/Q Change
Operating Cash Flow
53.6M
↑ 98.5%
Investing Cash Flow
-123.9M
↑ 357.88%
Financing Cash Flow
103.6M
↓ 3226.62%
Q1 FY23Q/Q Change
Operating Cash Flow
32.6M
↓ 39.2%
Investing Cash Flow
-65.6M
↓ 47.09%
Financing Cash Flow
-3.8M
↓ 103.69%
Q2 FY23Q/Q Change
Operating Cash Flow
68.1M
↑ 108.72%
Investing Cash Flow
-40.4M
↓ 38.44%
Financing Cash Flow
238.1M
↓ 6331.95%

Technicals Summary

Sell

Neutral

Buy

Radnet Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Radnet Inc
Radnet Inc
0.6%
20.76%
62.56%
97.53%
181.09%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
8.08%
16.63%
21.52%
6.86%
172.51%
Agilent Technologies Inc.
Agilent Technologies Inc.
-0.21%
10.53%
-6.64%
6.48%
66.86%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
1.51%
3.85%
4.51%
23.2%
118.12%
Danaher Corp.
Danaher Corp.
8.95%
-2.54%
2.96%
12.93%
100.65%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
14.14%
12.2%
19.36%
28.01%
77.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Radnet Inc
Radnet Inc
645.0
645.0
2.32
0.46
0.05
0.02
NA
9.12
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
56.48
56.48
5.44
11.14
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
31.51
31.51
2.54
5.49
0.22
0.08
0.01
20.01
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.49
36.49
2.8
21.56
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
44.46
44.46
3.28
7.61
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
33.95
33.95
1.63
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Radnet Inc
Radnet Inc
Buy
$2.6B
181.09%
645.0
0.25%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$47.4B
172.51%
56.48
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.7B
66.86%
31.51
18.15%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$214.9B
118.12%
36.49
13.99%
Danaher Corp.
Danaher Corp.
Buy
$186.1B
100.65%
44.46
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$44.9B
77.62%
33.95
9.06%

Institutional Holdings

  • BlackRock Inc

    13.14%
  • Vanguard Group Inc

    6.22%
  • Beck, Mack & Oliver LLC

    4.76%
  • State Street Corporation

    3.23%
  • Jb Capital Partners LP

    3.13%
  • Dimensional Fund Advisors, Inc.

    2.57%

Company Information

radnet, inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the united states based on the number of locations and annual imaging revenue. radnet has a network of 340+ owned and/or operated outpatient imaging centers. radnet's core markets include california, delaware, maryland, new jersey, and new york. together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, radnet has a total of approximately 7,300 employees.

Organization
Radnet Inc
Employees
6946
CEO
Dr. Howard G. Berger M.D.
Industry
Health Services

FAQs